Jumpei Ito
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jumpei Ito has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Fumito Yamazaki
Department of Pediatrics Keio University School of Medicine Tokyo Japan
4 shared publications- Haruko Shima
Department of Pediatrics Keio University School of Medicine Tokyo Japan
4 shared publications Hiroyuki Shimada
Department of Pediatrics Keio University School of Medicine Tokyo Japan
3 shared publications- Hiroyuki Shimada
Department of Pediatrics, Keio University School of Medicine, Tokyo
2 shared publications - Kyohei Isshiki
National Center for Child Health and Development
2 shared publications Risako Narukama
Department of Pediatrics, Keio University School of Medicine, Tokyo
2 shared publications
Latest Publications
- 9 June 2026
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 48 (6) , e277-e278
Letter to the Editor: Primary Extraosseous Ewing Sarcoma of the Right L5 Nerve Root Mimicking a Schwannoma
- 9 June 2026
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 48 (6) , e277-e278
Letter to the Editor: Primary Extraosseous Ewing Sarcoma of the Right L5 Nerve Root Mimicking a Schwannoma
- Open Access
- 1 January 2026
- Published by Wiley in Pediatrics International
- Vol. 68 (1) , e70469
Imaging–Pathology Discordance During Neoadjuvant Chemotherapy for Pediatric Osteosarcoma
- 1 January 2026
- Published by Wiley in Pediatrics International
- Vol. 68 (1) , e70469
Open AccessImaging–Pathology Discordance During Neoadjuvant Chemotherapy for Pediatric Osteosarcoma
- 6 July 2023
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 45 (7) , e915-e916
Refractory Burkitt Lymphoma With False-positive and False-negative Mass Detected on Positron Emission Tomography-computed Tomography After Chemotherapy
A 4-year-old boy with an abdominal mass extending from the spleen to the lower umbilicus was diagnosed with Burkitt lymphoma stage III. Because the fluorodeoxyglucose uptake on positron emission tomography (PET)-computed tomography of the residual splenic tumor remained elevated, splenectomy was performed. The PET-positive area was composed of inflammatory infiltrates, whereas the PET-negative area was composed of a viable tumor surrounded by necrotic or dying tumor cells. The residual tumor may have been false-negative for PET because of its poor proliferative potential. In this case, the comparison of PET-computed tomography and pathologic findings demonstrates the simultaneous presence of a false-positive inflammatory lesion and a false-negative residual tumor.
- 6 July 2023
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 45 (7) , e915-e916
Refractory Burkitt Lymphoma With False-positive and False-negative Mass Detected on Positron Emission Tomography-computed Tomography After Chemotherapy
A 4-year-old boy with an abdominal mass extending from the spleen to the lower umbilicus was diagnosed with Burkitt lymphoma stage III. Because the fluorodeoxyglucose uptake on positron emission tomography (PET)-computed tomography of the residual splenic tumor remained elevated, splenectomy was performed. The PET-positive area was composed of inflammatory infiltrates, whereas the PET-negative area was composed of a viable tumor surrounded by necrotic or dying tumor cells. The residual tumor may have been false-negative for PET because of its poor proliferative potential. In this case, the comparison of PET-computed tomography and pathologic findings demonstrates the simultaneous presence of a false-positive inflammatory lesion and a false-negative residual tumor.
- 24 September 2021
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (2) , e29368
Potential benefits of rapid genetic testing for germline WT1 in infants with bilateral renal tumors: A case report
- 24 September 2021
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (2) , e29368
Potential benefits of rapid genetic testing for germline WT1 in infants with bilateral renal tumors: A case report
- 16 July 2019
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 66 (10) , e27926
Haploidentical stem cell transplantation with posttransplant cyclophosphamide for refractory systemic juvenile xanthogranuloma
Juvenile xanthogranuloma (JXG) is a generally benign, self‐limited histiocytic disorder, which belongs to non‐Langerhans cell histiocytoses (non‐LCH). However, systemic JXG can be fatal in rare cases. We present the case of an 11‐year‐old female with systemic JXG, who experienced repeated vertebral compression fractures and did not fully respond to systemic chemotherapy. Based on its reported efficacy in LCH, the patient underwent human leukocyte antigen‐haploidentical hematopoietic stem cell transplantation (HSCT) with posttransplant cyclophosphamide. The patient did not suffer major complications and has not experienced relapse for 13 months since HSCT. HSCT may be a potential treatment option for patients with refractory non‐LCH.
- 16 July 2019
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 66 (10) , e27926
Haploidentical stem cell transplantation with posttransplant cyclophosphamide for refractory systemic juvenile xanthogranuloma
Juvenile xanthogranuloma (JXG) is a generally benign, self‐limited histiocytic disorder, which belongs to non‐Langerhans cell histiocytoses (non‐LCH). However, systemic JXG can be fatal in rare cases. We present the case of an 11‐year‐old female with systemic JXG, who experienced repeated vertebral compression fractures and did not fully respond to systemic chemotherapy. Based on its reported efficacy in LCH, the patient underwent human leukocyte antigen‐haploidentical hematopoietic stem cell transplantation (HSCT) with posttransplant cyclophosphamide. The patient did not suffer major complications and has not experienced relapse for 13 months since HSCT. HSCT may be a potential treatment option for patients with refractory non‐LCH.
- 5 July 2019
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 66 (10) , e27911
Testicular involvement without testicular enlargement in a young male with atypical chronic myeloid leukemia
- 5 July 2019
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 66 (10) , e27911
Testicular involvement without testicular enlargement in a young male with atypical chronic myeloid leukemia